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Abbreviations 
 
5-HT1B  Serotonin 5-HT1B receptor 
5-HT2B  Serotonin 5-HT2B receptor 
A2AR  Adenosine A2A receptor  
AT1R  Angiotensin II type 1 receptor 
AT2R  Angiotensin II type 2 receptor 
β1AR  β1 adrenergic receptor 
β2AR  β2 adrenergic receptor 
CCR5  C-C chemokine receptor type 5 
CB1  Cannabinoid receptor 1 
CLR  Calcitonin receptor-like receptor 
CRF   Corticotropin-releasing factor 
CRFR1 Corticotropin-releasing factor receptor 1 
CXCR  C-X-C chemokine receptor  
D3R   Dopamine 3 receptor 
ECD  Extracellular domain 
ECL  Extracellular loop 
ET-1  Endothelin-1 
FFAR1 Free fatty acid receptor 1 
GCGR  Glucagon receptor  
GIP  Gastric inhibitory polypeptide 
GIPR  Gastric inhibitory polypeptide receptor 
GLP1   Glucagon-like peptide-1 
GLP1R  Glucagon-like peptide-1 receptor  
GPCR  G protein-coupled receptor 
H1R  Histamine H1 receptor 
ICL  Intracellular loop 
LB  Lobe 
mGLUR metabotropic glutamate receptor 
M2R   M2 muscarinic acetylcholine receptor 
M3R   M3 muscarinic acetylcholine receptor 
NMR  Nuclear magnetic resonance 
N/OFQ  Nociception/orphanin FQ peptide 
OR  Opioid receptor 
PAR1  Proteinase-activated receptor 1 
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RAMP1 (R1)  Receptor activity modifying protein 
S1P1R  Sphingosine-1-phosphate 1 receptor 
SCAM  Scanning cysteine accessibility method  
TM  Transmembrane 
VFT  Venus fly trap 
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Abstract 
The extracellular loops (ECLs) of G protein-coupled receptors (GPCRs) can bind directly to 
docked orthosteric or allosteric ligands, they can contain transient contact points for ligand 
entry into the transmembrane (TM) bundle and they can regulate the activation of the 
receptor signalling pathways. Of the three ECLs, ECL2 is the largest and most structurally 
diverse reflecting its functional importance. This has been shown through biochemical 
techniques and has been supported by the many subsequent crystal structures of GPCRs 
bound to both agonists and antagonists. ECL2 shares common structural features between 
(and sometimes across) receptor sub-families and can facilitate ligand entry to the TM core or 
act directly as a surface of the ligand-binding pocket. Structural similarities seem to underpin 
common binding mechanisms; however, where these exist, variations in primary sequence 
ensure ligand-binding specificity. This review will compare current understanding of the 
structural themes and main functional roles of ECL2 in ligand binding, activation and 
regulation of the major families of GPCRs. 
 
Keywords 
GPCR; Extracellular loop; ligand-binding; receptor activation; signalling; family B. 
 
1 Introduction 
G protein-coupled receptors (GPCRs) are a super-family of receptors. There are over 800 
different GPCRs in humans and they are involved in almost every physiological process 
(Fredriksson et al., 2003, Bockaert and Pin, 1999, Rosenbaum et al., 2009). This makes them 
ideal targets for drugs and thus between 25-50% of therapeutics interact with these receptors 
(Salon et al., 2011). GPCRs undergo conformational changes that result in active and inactive 
conformations (Cherezov et al., 2007, Rasmussen et al., 2011b). Both drugs and natural 
agonists function by stabilising a particular conformation (Jazayeri et al., 2015). For most 
ligands to bind to a specific receptor propagating the signalling response, the extracellular 
regions of the receptor (specifically the extracellular domain (ECD) and the extracellular 
loops (ECLs)) are particularly important. It is known that the ECLs of GPCRs can permit or 
facilitate ligand-entry into the TM bundle, hold ligands within the TM domain, direct ligands 
towards their binding site, change the shape of the binding pocket or bind directly to 
orthosteric or allosteric ligands (Wheatley et al., 2012).  
 
GPCR crystal structures and functional studies have shown that ECL2 is particularly 
important. ECL1 and ECL3 are often short loops that run parallel to the membrane 
connecting TM 2/3 and TM 6/7 respectively, however ECL2 is longer and shows much 
greater variation with its structural features (Venkatakrishnan et al., 2013). As well as this 
structural diversity, ECL2 is vital for ligand binding and the subsequent activation of the 
receptor (Wheatley et al., 2012). 
 
The importance of ECL2 (connecting TM4 and TM5) was first identified through chimeric 
receptor experiments and mutagenesis studies of this domain (Olah et al., 1994, Walker et al., 
1994, Fitzpatrick and Vandlen, 1994). Even in receptors with known TM ligand-binding 
pockets, the ECLs were implicated in early stage ligand-binding and presentation to the TM 
binding site (Colson et al., 1998, Perlman et al., 1997). In many cases ECL2 residues have 
been implicated in direct or indirect ligand-binding due to the location, flexibility and 
sequence variability of the loop (Kim et al., 1996, Wheatley et al., 2012). 
 
Given the large recent increase in structural information, highlighting the importance of 
ECL2 in the extracellular region, this review will specifically focus on ECL2. The crystal 
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structures, together with a large amount of biochemical data, have implicated ECL2 in many 
key aspects of receptor function (e.g. ligand binding and activation) and this loop often has a 
role in the current “hot topics” of receptor function (e.g. biased signalling, allosteric 
modulation). This review will start by summarising the structural information known for this 
loop. This will be followed by a comparison of the functional characteristics of ECL2 in the 
super-family. Finally, we will discuss whether this loop acts as a molecular “gatekeeper” 
controlling the course of activation of the receptor. 
 
2 Structure of ECL2 
A number of GPCR crystal structures have now been published. These have provided 
important information with respect to both structure and contact sites with the bound ligand. 
In this section these structures are illustrated with ECL2 specifically highlighted. Key 
structural information has also been summarised. The crystal structures often include 
additional, useful ‘non-structural’ information (e.g. contact sites with a bound ligand), which 
will be discussed later in the review. For clarity the receptors have been grouped according to 
phylogenetic similarity or in some cases a shared structural or functional property.  
 
2.1 An ECL2 β-hairpin structure forms an extracellular cap over the TM bundle in 
receptors with hydrophobic or covalently attached ligands 
The unique structural properties of ECL2 were first highlighted in the crystal structure of 
bovine rhodopsin (see figure 1 and table 1), which found ECL2 to be an antiparallel β-sheet 
in a hairpin formation (β-hairpin) extending deep into the centre of the TM bundle 
(Palczewski et al., 2000). ECL2 makes extensive contacts between both the retinal ligand and 
the extracellular regions. It also associates with the extracellular N-terminus and ECLs to 
form an extracellular cap over the TM bundle, closing off the ligand-binding pocket to the 
extracellular side (the “closed” ECL2 position). 
 
This closed extracellular cap involving ECL2 is a feature that is also present in the 
sphingosine-1-phosphate 1 (S1P1) receptor (see figure 1 and table 1) and the GPR40 (free 
fatty acid receptor 1, FFAR1). In both these structures, ECL2 contains a β-sheet structure. In 
the S1P1R the N-terminal ECD folds over and packs tightly with ECL1 and ECL2 forming a 
cap over the receptor. This creates the top surface to a ligand-binding pocket (Hanson et al., 
2012). In GPR40 the β-sheet structure is preceded by an auxiliary loop (Srivastava et al., 
2014). The GPR40 ECL2 has low flexibility and functions as a cap over the binding site, 
similar to that observed with the S1P1R. 
 
2.2 The ECL2 β-hairpin structure is “open” in the family A GPCR peptide, opioid and 
chemokine receptor sub-types 
The ECL2 β-hairpin structure is common in many GPCRs and is a feature shared across 
receptor sub-families. However, compared to its “closed” position in the extracellular capped 
receptors (with hydrophobic or covalently attached ligands) the loop is open for receptors 
with soluble ligands. “Open” means that the loop “allows” or mediates extracellular access to 
the TM bundle. These include the peptide-binding receptors as well as the opioid and 
chemokine receptors (both in the same sub-family (γ) of the family A receptors; see figure 1 
and table 1) (Wu et al., 2010, Park et al., 2012, Wu et al., 2012, Granier et al., 2012, Tan et 
al., 2013, Manglik et al., 2012). The nociceptin/orphanin FQ (N/OFQ) peptide receptor shares 
high sequence homology with the opioid GPCRs but has distinct pharmacology. ECL2 has 
the same β-sheet hairpin structure as the opioid and chemokine receptors (Thompson et al., 
2012). The peptide binding endothelin ETB receptor also shares this β-hairpin structure 
(Shihoya et al., 2016).  
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The β-hairpin structure is also present in the protease activated receptor 1 (PAR1). This is 
part of the δ-subfamily of the family A GPCRs, which include the glycoprotein receptors, the 
purinergic receptors and the olfactory receptors (Zhang et al., 2012). However PAR1 has 
been included in this section due to its activation through a (tethered) peptide ligand and a 
similar ECL2 structure. 
 
2.3 There are a variety of ECL2 structures within the aminergic receptors 
The aminergic receptors of the histamine H1 receptor (H1R), dopamine D3 receptor (D3R), 
muscarinic (M1, M2, M3, M4) receptors, serotonin receptors, β1AR and β2AR all have an 
open ECL2 conformation with this loop forming the top of a ligand-binding pocket (see 
figure 2 and table 1). There are some structural differences between the receptors in this 
group. β1AR and β2AR have an α-helical ECL2 structure (Warne et al., 2008, Cherezov et 
al., 2007). ECL2 of the β2AR was exposed at the surface and has an intra-loop disulphide 
bond as well as the conserved disulphide bond with TM3. The loop also made contacts with 
ECL1 and had a glycosylation site at position N187. The D3R ECL2 lacks any secondary 
structure and is shorter than the βARs ECL2s. Despite this, it still forms a binding pocket that 
interacts with various ligands that were studied and may be important for ligand specificity 
(Chien et al., 2010).  
 
The four available muscarinic acetylcholine receptor structures (M1, M2, M3 and M4) have 
ECL2 domains that also lack secondary structure but adopt a conformation similar to the β-
hairpin structure in many other GPCRs (see figure 2 and table 1); this is “open” allowing 
ligand entry to a deep binding pocket (Haga et al., 2012, Kruse et al., 2012, Thal et al., 2016). 
The H1R ECL2 also lacks secondary structure but partially covers the ligand-binding pocket 
(Shimamura et al., 2011). In the 5-HT1B (serotonin) receptor structure, ECL2 forms a loop 
that partially covers the ligand-binding pocket (Wang et al., 2013). Whereas in the 5-HT2B 
receptor structure, there is an additional helical turn at the extracellular end of TM5 (Wacker 
et al., 2013). This shortens the segment of ECL2 that is connected to TM3 through the 
conserved disulphide bond, causing an inward shift and a constraint on the position of the 
extracellular end of TM5. This may explain the differing conformations seen in the crystal 
structures of the 5-HT1B and 5-HT2B receptors in the presence of the same ligand. 
 
2.4 ECL2 within the adenosine receptors has different structural features depending on the 
crystal structure  
The ECL2 α-helix observed in the β1AR and β2AR is also present in the agonist-bound 
A2AR adenosine receptor (Lebon et al., 2011) but not in the antagonist bound structure 
(Jaakola et al., 2008), however part of the loop was missing in this structure (see table 1).  
 
There is also a β-strand that forms hydrogen bonds with a second β-strand in ECL1; however 
the degree of hydrogen bonding varies between antagonist- and agonist-bound structures. In 
the antagonist-bound structure there is an extensive disulphide bond network with three 
bonds connecting ECL1 and ECL2 and an intra-loop disulphide bond in ECL3 that creates a 
rigid open structure exposing the ligand-binding cavity (Jaakola et al., 2008). 
 
2.5 ECL2 within the family B GPCRs is a loop (with no secondary structure) open to the 
TM bundle 
Crystal structures have been solved for two family B GPCRs (Hollenstein et al., 2013, Siu et 
al., 2013, Jazayeri et al., 2016). The corticotropin releasing factor receptor 1 (CRFR1) and the 
glucagon receptor (GCGR) lack the β-sheet or α-helix present in so many of the family A 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
GPCRs (see figure 2 and table 1). Both receptors have a similar ECL2 structure, where the 
loop extends from TM4 towards the middle of the TM bundle before twisting 90° to cover 
the binding pocket and twisting back 90° to form TM5. This is more representative of some 
of the aminergic sub-family of the family A GPCRs (e.g. the muscarinic and dopamine 
receptors) (Chien et al., 2010, Haga et al., 2012, Kruse et al., 2012, Park et al., 2012). 
 
2.6 ECL2 within the family C GPCRs is a β-hairpin in a different position to the family A 
β-hairpin 
Both family C GPCR structures (mGluR1 and mGluR5) have a β-hairpin structure within 
ECL2 (Wu et al., 2014, Dore et al., 2014), however this is angled more towards TM6 and 7 
(especially mGluR1) than the other β-hairpin receptors in family A (see table 1). Any role in 
receptor activation or ligand-binding is not known but ECL2 is not likely to be a major factor 
in agonist-interaction as the “venus fly-trap” process in the ECD of family C GPCRs is very 
well established.  
 
2.7 Structural differences in ECL2 between inactive and active structures 
A number of active structures of GPCRs have now been published. These are receptors 
bound to agonist and in some cases the G protein or G protein mimetic antibody. 
 
Crystal structures and NMR analysis of the µOR have shown that the β-hairpin structure of 
ECL2 moves upon receptor activation however this movement is slight, creating subtle 
differences in the ligand binding pocket (Sounier et al., 2015, Huang et al., 2015). In the M2 
muscarinic receptor active structure, there is an inward movement (towards the TM bundle 
centre) of both ECL2 and ECL3 that creates an orthosteric binding pocket too small for the 
binding of an inverse agonist (Kruse et al., 2013). Binding of the endothelin-1 (ET-1) agonist 
to the ETB receptor caused a small movement of the ECL2 β-hairpin that together with the N-
terminal tail, created a “closed” lid structure and almost irreversible binding of the ET-1 
ligand (Shihoya et al., 2016). In the active β2AR structures, there is very little movement of 
ECL2 (Rasmussen et al., 2011b, Rasmussen et al., 2011a). 
 
2.8 Summary of the ECL2 structures 
In the solved family A and family C crystal structures, the most common ECL2 conformation 
is a β-hairpin (see table 1). These include receptors for lipid soluble ligands and the family A 
peptide ligands (for example the opioid and chemokine receptors). Perhaps surprisingly, this 
is not a feature of the peptide binding family B receptor ECL2 structures. Instead these 
contain a loop structure more similar to some of the family A aminergic receptors (e.g. 
muscarinic receptors). There are exceptions to these categories, most obviously the β1AR and 
β2AR, which both contain an α-helical ECL2 structure. Across the solved structures, the 
ECL2 domain can be open or closed to the orthosteric binding pocket in the TM bundle. 
Receptors with covalently attached or lipid ligands have ECL2 in a closed position over the 
top of the TM bundle. Receptors with soluble ligands often have ECL2 in an open position, 
however there is flexibility of the loop. The conformation changes that occur during GPCR 
activation are largest on the intracellular side (Rasmussen et al., 2011b). The movement of 
ECL2 is more subtle however this can result in large functional effects. 
 
3 ECL2 and receptor function 
 
3.1 Key features and motifs 
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3.1.1 A conserved TM3-ECL2 disulphide bond across the GPCR superfamily forms a 
structural constraint 
There is a conserved ECL2 cysteine residue across the GPCR super-family as a whole, 
forming a disulphide bond with a cysteine residue at the top of TM3 (Wheatley et al., 2012). 
This has been thought to be necessary for the structural integrity of the loop and therefore 
receptor function (Venkatakrishnan et al., 2013). In some cases it has been shown to be 
essential for receptor function;  With the C5aR, the double alanine substitution did not 
produce a signalling response upon ligand stimulation (however constitutively active 
substitutions remained active) (Klco et al., 2005). In the chemokine CCR8 receptor, the 
conserved disulphide bond between TM3 and ECL2 was essential for receptor function with 
the CCL peptide agonist but also small molecular antagonists that bind deeper in the TM 
bundle (Barington et al., 2016). However in other receptors the disulphide bond is 
functionally redundant; Double alanine mutations (to remove the bond and any free 
sulphydryl groups) on the family A adenosine A2A receptor (Naranjo et al., 2015) and the 
family B CGRP and GLP1 receptors (Woolley et al., 2013, Mann et al., 2010) retained 
receptor function.  
 
3.1.2 Conserved motifs in family B GPCRs 
In a number of the family B receptors (CGRP receptor, GCGR and GLP1R), several residues 
have consistently been shown to have importance in ligand binding and the subsequent 
activation of the receptors. These include a conserved basic residue at the start of ECL2, an 
acidic residue before the conserved cysteine and a tryptophan immediately after the cysteine 
(forming a conserved family B CW motif); (Woolley et al., 2013, Siu et al., 2013, Koole et 
al., 2012). This central ECL2 tryptophan residue was also important for ligand binding and 
activation of the CRF1R (Gkountelias et al., 2009). 
 
3.2 The role of ECL2 in ligand binding and receptor activation in the GPCR super-family 
 
3.2.1 ECL2 can control ligand entry into the orthosteric binding pocket 
The extracellular region of GPCRs can be split into two categories; those with a closed 
orthosteric ligand binding pocket (to the extracellular side) and those with an open orthosteric 
ligand binding pocket (Venkatakrishnan et al., 2013). 
 
The closed ligand binding pocket group are the receptors corresponding with the extracellular 
capped receptors in section 2.1. In these receptors ECL2 and the rest of the extracellular 
region cover the ligand binding pocket, preventing ligand access from the extracellular side. 
These receptors have either a unique, covalently attached retinal ligand in the TM bundle of 
the bovine rhodopsin receptor that makes contacts with ECL2 (Palczewski et al., 2000), or 
lipid ligands that gain access to the ligand-binding pocket through the lipid bilayer (S1P1R 
and GPR40) (Hanson et al., 2012, Srivastava et al., 2014). However with GPR40, a ligand-
binding pocket was predicted that would require extracellular entry (Srivastava et al., 2014). 
This type of ligand entry (through the lipid bilayer) has also been proposed for lipophilic 
drugs (e.g. vorapaxar with the PAR1) (Zhang et al., 2012). 
 
Those receptors with an open ligand-binding pocket bind to water soluble ligands, which gain 
entry to the TM bundle from the extracellular side (Venkatakrishnan et al., 2013).  
 
In the case of the opioid, chemokine and family A peptide GPCRs, the ECL2 regions of these 
receptors have the same β-hairpin structure as the extracellular capped receptors with the 
closed pocket, however this is open to the orthosteric binding pocket allowing ligand entry to 
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the binding pocket from the extracellular side (Wu et al., 2010, Park et al., 2012, Wu et al., 
2012, Granier et al., 2012, Tan et al., 2013, Manglik et al., 2012). Often ECL2 forms part of 
the binding pocket, interacting with the bound ligand. In a more unique case, activation of 
PAR1 occurs when thrombin cleaves the N-terminal ECD, exposing a tethered peptide ligand 
that binds to the TM bundle (that is speculated to occur following interactions with the ECLs) 
(Zhang et al., 2012). 
 
3.2.2 ECL2 can function as part of the orthosteric binding site 
Residues in ECL2 can face the orthosteric binding site and be involved in ligand binding. 
These residues can be aromatic, hydrophobic, polar and charged. In the V1AR vasopressin 
receptor, aromatic residues that are highly conserved in the neurohypophysial GPCR sub-
family were important for agonist binding and receptor activation (Conner et al., 2007). 
Tyrosine residues in the chemokine CCR8 receptor were important for agonist and antagonist 
binding (Barington et al., 2016). Aromatic and hydrophobic residues of ECL2 line the 
orthosteric binding pocket of the ETB receptor (Shihoya et al., 2016). The C-terminus of the 
ET-1 ligand fitted into a hydrophobic binding pocket, which included an ECL2 
phenylalanine. Hydrophobic residues of the ET-1 α-helix interacted with both aromatic and 
hydrophobic residues of ECL2, which tightly holds the ligand in place with the β-sheet 
structure. The importance of hydrophobic residues in ECL2 was shown in the dopamine D1 
receptor (Mente et al., 2015). An ECL2 leucine residue is important for agonist binding to 
this receptor. 
 
Both acidic and basic residues of ECL2 have been shown to be important in forming the 
orthosteric binding site. Mutation of these residues in family A receptors have had a 
detrimental effect on ligand-binding and receptor activation (Walker et al., 1994, Kim et al., 
1996, Moro et al., 1999). Acidic residues have been shown to be important in the opioid 
receptors. An ECL2 aspartate residue (D187)  in the D3R is important in the tolerance to 
different receptor agonists (Gil-Mast et al., 2013). The ECL2 of the N/OFQ peptide receptor 
is enriched with aspartate and glutamate resides making this loop acidic and a predicted site 
of docking with the peptide antagonist UFP-101 (Thompson et al., 2012). In the H1R an 
ECL2 lysine (K179) forms part of an anion-binding site at the entrance to the ligand-binding 
pocket, which is a feature unique to the H1R-doxepin (antagonist) complex. K179 and the 
preceding aspartate (D178) are also able to interact with specific antagonists (Shimamura et 
al., 2011). 
 
3.2.3 ECL2 is involved in ligand selectivity 
ECL2 residues can be involved in the selective binding to agonists, antagonists and inverse 
agonists. Residues in the C-terminus of the cannabinoid receptor 1 (CB1) ECL2 were 
important for agonist binding but not inverse agonist binding (Ahn et al., 2009). Modelling 
also implicated ECL2 in inverse agonist binding in the cannabinoid receptor subtype CB2 
(Hu et al., 2016). Analysis of the crystal structures of β1AR and serotonin receptor crystal 
structures found ECL2 to be involved in the binding to different ligands to the same receptor 
(β1AR) or an altered docking of the same ligand to different receptors (5-HT1B and 5-HT2B) 
(Shukla et al., 2014). 
 
In the two angiotensin receptor subtypes (AT1R and AT2R), ECL2 showed flexibility and 
variability. This became a target for selective ligand design that results in the creation of an 
agonist analogue with 18,000 fold higher selectivity for AT2R (Magnani et al., 2014). 
 
3.2.5 ECL2 affects receptor binding kinetics 
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In the unliganded structure of ETB receptor, the receptor is “open” creating a large cavity 
(Shihoya et al., 2016). Following binding of ET-1 to the ETB receptor, ECL2 and the N-
terminal tail form a lid which covers the orthosteric binding pocket. This “closed” structure 
would explain the incredibly slow dissociation rate of ET-1 from its receptor (Clozel et al., 
1989, Fischli et al., 1989, Takasuka et al., 1994). The scanning cysteine accessibility method 
(SCAM) was used to investigate the exposure of the AT1R ECL2 domain to the aqueous 
environment in different receptor states (Unal et al., 2010). In the un-liganded receptor, a 
segment either side of the conserved disulphide bond was available, suggesting an open 
conformation. Upon binding to an agonist or inverse agonist, ECL2 acted like a lid albeit in 
different conformations. ECL2 was involved in slowing down the rate of dissociation of 
ligands but also adopted different conformations according to the functional state of the 
receptor. This dynamic effect of ECL2 was also observed with the M2R, where a reduction of 
loop flexibility caused by the addition of a disulphide bond between ECL2 and TM7 reduced 
the ligand binding affinity (Avlani et al., 2007).  
 
In the M2 muscarinic receptor, the only ECL2 residue that formed interactions with the 
bound antagonist was a phenylalanine (F181). This phenylalanine is absent in the equivalent 
position in the M3 receptor (L225) and creates a larger binding pocket. In molecular dynamic 
simulations, the M2R binding pocket was found to be more mobile than M3R and the inverse 
agonist tiotropium dissociated from the M3 receptors more slowly. However reciprocal 
mutagenesis of these ECL2 residues suggested these residues alone were not sufficient to 
explain the different off rates (Haga et al., 2012, Kruse et al., 2012). 
 
3.1.2 ECL2 is important for ligand binding in the family B GPCRs 
Cross-linking experiments identified contact sites between the CRFR1 and radiolabelled 
sauvagine (Assil-Kishawi and Abou-Samra, 2002). Disuccinimidyl suberate (DSS) was used 
to form cross-links between ε amino groups of lysine residues that have a molecular distance 
of 11.4 Å. This technique revealed that K257 in the ECL2 domain was in close proximity to 
K16 of the ligand sauvagine. Cysteine trapping experiments with secretin and its receptor 
also showed that the N terminus of the ligand was in close proximity to ECL2, with position 
2 of the peptide closer to the N-terminal half of ECL2 and the C-terminal half of ECL2 closer 
to positions 5, 6 and 7 (Dong et al., 2012, Dong et al., 2016).    
 
3.3 ECL2 is a proposed site of allosteric modulation 
There is evidence that residues of ECL2 are required for allosteric enhancement of agonist 
signalling (Kennedy et al., 2014, Peeters et al., 2012) in the family A GPCRs. In the M2R 
crystal structure with a bound positive allosteric modulator (LY2119620), the allosteric site 
was situated above the orthosteric binding pocket and involved interactions with the ECLs. 
ECL2 interactions were hydrogen bonding with E172 and stacking interactions with Y177 
(Kruse et al., 2013). Allosteric modulation involving ECL2 has been shown for the M1R 
through interactions with another tyrosine residue (Y179) and a phenylalanine residue (F182) 
(Abdul-Ridha et al., 2014). ECL2 in the somatostatin receptors has been used as a successful 
antibody target to induce an agonist-like response (Leu and Nandi, 2010).  
 
It is likely that ECL2 can facilitate binding to allosteric modulators across all GPCR families. 
For example, in the family C mGluR1, ECL2 forms the top of a ligand binding pocket to the 
negative allosteric modulator FITM (Wu et al., 2014) and ECL2 was involved in the binding 
of negative allosteric modulators in the family C mGluR2 (Lundstrom et al., 2011). It is 
interesting to speculate that this site is similar to the orthosteric binding pocket in the other 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
 
GPCR families and may reflect a loss of direct ECL2/ligand interaction in this specific sub-
family.  
 
It is well established that the affinity of a ligand can change based on the activation 
conformation of the receptor. As different intracellular interactions (such as beta-arrestin or G 
protein promiscuity) can create “different” conformations, it is not unreasonable to speculate 
that this will have a subsequent effect on the stability of ECL2 interactions with the ligand 
and subsequent modulation of signalling. This effect can lead to allosterism or in some cases, 
biased agonism. 
 
3.4 ECL2 may mediate biased agonism in the two major GPCR families. 
Biased agonism is a phenomenon of growing interest in receptor biology research. Biased 
agonism means that two ligands of the same receptor activate different signalling pathways or 
have different preferences for activation of multiple pathways (Shukla et al., 2014). 
Activation of particular signalling pathways has been linked to the development of certain 
diseases (Luttrell, 2014). Understanding the physiological effects of biased agonism may 
provide a platform for the design of drugs that target only the relevant signalling pathway; 
thereby increasing efficacy and reducing off-target effects.  
 
The involvement of ECL2 in biased agonism has been shown in family B GPCRs using 
alanine-substitution experiments. Three GLP-1R ligands (GLP-1, exendin-4 and 
oxyntomodulin) that demonstrated biased agonism at this receptor all showed some 
requirement for ECL2. GLP-1 and exendin-4 ligands required ECL2 for cAMP and Ca2+ 
signalling but not for ERK1/2 signalling. Oxyntomodulin required ECL2 for the coupling of 
the ligand to the ERK1/2 and cAMP signalling pathways (Ca2+ was not tested for 
oxyntomodulin) ((Wootten et al., 2016, Koole et al., 2012). Mutagenesis and modelling 
studies in the family B CGRP receptor family show that the three receptor activity modifying 
proteins (RAMPs) can induce different ECL2 conformations with distinct binding pockets for 
CGRP and adrenomedullin, altering their signalling profile (Weston et al., 2016). 
 
ECL2 has also been shown to be involved in biased agonism for family A GPCRs. In the 
PAR1 receptor, glycosylation of ECL2 stimulated a G12/13 signalling response compared with 
a mutant receptor that lacked glycosylation, which produced a Gq signalling response 
resulting in different cellular effects (Soto et al., 2015). Mutagenesis of the ECL2 region of 
the M1 and M2 muscarinic receptors produced receptors that both had biased signalling 
responses to different ligands. In the M1R, ECL2 was involved in signalling bias between 
Ca2+ and ERK1/2 pathways (Keov et al., 2014) and in ERK1/2 signalling in the M2R 
(Gregory et al., 2010). This shows that there are inter-relationships between biased agonism 
and allosteric modulation discussed in section 3.3) as some of the muscarinic ligands 
demonstrating biased agonism were bitopic ligands (having both orthosteric and allosteric 
binding properties). 
 
3.5 A role for ECL2 on basal signalling 
Mutagenesis of two ECL2 phenylalanine residues in the human histamine 4 receptor (H4R) 
resulted in reduced constitutive and ligand-induced receptor activation showing a direct 
involvement in receptor activation for this domain (Wifling et al., 2015a, Wifling et al., 
2015b). Conversely, constitutive activity resulting from mutagenesis has led to speculation 
that this domain may constrain the receptor in its inactive state through interactions with the 
TM domain (Klco et al., 2005). In the melanocortin receptor, ECL2 is much shorter and does 
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not interact with the TM core, leading to a higher constitutive activity (Holst and Schwartz, 
2003).  
 
3.6 Summary 
In the largest two families of GPCRs, ECL2 almost always forms part of the ligand-binding 
pocket. The variation in shape and physicochemical properties of ECL2 gives it a key 
functional role in ligand selectivity and binding kinetics. The location of ECL2 at the top of 
the receptor allows it to function as one side of the orthosteric binding pocket (on the 
underside) but also as a site for allosteric modulation (the top side). ECL2 is also at the 
interface of ligand binding and receptor activation, allowing it to control aspects of 
signalling, such as biased signalling and constitutive activity. 
 
4 Discussion 
ECL2 is arguably the most structurally diverse and functionally important ECL of the GPCR 
super-family. This has been shown in the solved crystal structures and also through 
biochemical analysis of the ECLs and is a common phenomenon across all the GPCR sub-
families. ECL2 has a more complex structure than the other ECLs broadly forming a surface 
of the ligand-binding pocket that can act as a “lid” in either an open or closed position. The 
conformation and physicochemical properties of the ECL2 domain can influence the size and 
shape of the ligand-binding pocket and determine ligand selectivity. ECL2 can form direct 
interactions with agonists, antagonists, inverse agonists and allosteric modulators and its 
conformation can change upon binding to these ligands. ECL2 can also have a substantial 
impact on ligand on/off rates. ECL2 has roles in the super-family in ligand binding, allosteric 
modulation, conformational activation or biased signalling. Some of these functions can be 
retained even if ECL2 has lost direct agonist contact (such as allosterism in the family C 
receptors). 
 
ECL2 often functions as the “lid” of the “box” that is the ligand-binding pocket. As such it 
can often be thought of as one of the sides of the ligand-binding pocket. This ECL2 lid can be 
open or closed and can control the entry and exit of ligands to their receptors and the kinetics 
of this process. This is an exciting and important target for rational drug design.    
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Figure legends 
 
Figure 1. Crystal structures of the extracellular capped, opioid and chemokine GPCRs. 
The crystal structures of bovine rhodopsin (PDB 1F88), S1P1R (PDB 3V2Y), µOR (PDB 
4DKL) and CXCR1 (PDB 2LNL) are presented. Each row shows the receptor in two 
orientations. These are planar to the membrane (left box) and perpendicular to the membrane 
from the extracellular side (right box). ECL2 is highlighted red and the remainder of the 
receptor light blue. 
 
Figure 2. Crystal structures of the aminergic and family B GPCRs. 
The crystal structures of β2AR (PDB 2RH1), M2R (PDB 3UON), D3R (PDB 3PBL) and 
CRFR1 (PDB 4K5Y) are presented. Each row shows the receptor in two orientations. These 
are planar to the membrane (left box) and perpendicular to the membrane from the 
extracellular side (right box). ECL2 is highlighted red and the remainder of the receptor light 
blue. 
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Table 1. 
GPCR PDB group feature 
bovine 
rhodopsin 1F88 
covalently attached 
ligand β hairpin 
S1PR 3V2Y lipid receptor loop and β sheet 
GPR40  4PHU lipid receptor loop and β sheet 
LPA1 4Z34 lipid receptor loop, no secondary structure 
β1AR 2VT4 Aminergic α-helix 
β2AR 2RH1 Aminergic α-helix 
M1R 5CXV Aminergic (hairpin) loop, no secondary structure 
M2R 3UON Aminergic (hairpin) loop, no secondary structure 
M3R 4DAJ Aminergic (hairpin) loop, no secondary structure 
M4R 5DSG Aminergic (hairpin) loop, no secondary structure 
D3R 3PBL Aminergic loop, no secondary structure 
H1R 3RZE Aminergic loop, no secondary structure 
5-HT1B 4IAR Monoamine loop, no secondary structure 
5-HT2B 4IBR Monoamine loop, no secondary structure 
A2AR 2YDO purine nucleoside α-helix  and β sheet 
P2Y1 4XNV purinergic β hairpin 
δOR 4EJ4 opioid (peptide) β hairpin 
κOR 4DJH opioid (peptide) β hairpin 
µOR 4DKL opioid (peptide) β hairpin 
NORQ 4EA3 opioid (peptide) β hairpin 
ETBR 5GLH peptide ligand β hairpin 
OX2 4S0V peptide ligand β hairpin 
angiotensin 4YAY peptide ligand β hairpin 
PAR1 3VW7 cleaved peptide β hairpin 
CCR5 4MBS chemokine (peptide) β hairpin 
CXCR1 2LNL chemokine (peptide) β hairpin 
CXCR4 3ODU chemokine (peptide) β hairpin 
CRFR1 4K5Y family B loop, no secondary structure 
GCGR 4L6R family B loop, no secondary structure 
mGLUR1 4OR2 family C β hairpin 
mGLUR5 4OO9 family C β hairpin 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
 
References 
Abdul-Ridha, A., López, L., Keov, P., Thal, D. M., Mistry, S. N., Sexton, P. M., Lane, J. R., 
Canals, M. and Christopoulos, A. (2014) 'Molecular determinants of allosteric 
modulation at the M1 muscarinic acetylcholine receptor', J Biol Chem, 289(9), pp. 
6067-79. 
Ahn, K. H., Bertalovitz, A. C., Mierke, D. F. and Kendall, D. A. (2009) 'Dual role of the second 
extracellular loop of the cannabinoid receptor 1: ligand binding and receptor 
localization', Mol Pharmacol, 76(4), pp. 833-42. 
Assil-Kishawi, I. and Abou-Samra, A. B. (2002) 'Sauvagine cross-links to the second 
extracellular loop of the corticotropin-releasing factor type 1 receptor', J Biol Chem, 
277(36), pp. 32558-61. 
Avlani, V. A., Gregory, K. J., Morton, C. J., Parker, M. W., Sexton, P. M. and Christopoulos, A. 
(2007) 'Critical role for the second extracellular loop in the binding of both 
orthosteric and allosteric G protein-coupled receptor ligands', J Biol Chem, 282(35), 
pp. 25677-86. 
Barington, L., Rummel, P. C., Luckmann, M., Pihl, H., Larsen, O., Daugvilaite, V., Johnsen, A. 
H., Frimurer, T. M., Karlshoj, S. and Rosenkilde, M. M. (2016) 'Role of Conserved 
Disulfide Bridges and Aromatic Residues in Extracellular Loop 2 of Chemokine 
Receptor CCR8 for Chemokine and Small Molecule Binding', J Biol Chem, 291(31), pp. 
16208-20. 
Bockaert, J. and Pin, J. P. (1999) 'Molecular tinkering of G protein-coupled receptors: an 
evolutionary success', EMBO J, 18(7), pp. 1723-9. 
Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G., Thian, F. S., Kobilka, T. S., 
Choi, H. J., Kuhn, P., Weis, W. I., Kobilka, B. K. and Stevens, R. C. (2007) 'High-
resolution crystal structure of an engineered human beta2-adrenergic G protein-
coupled receptor', Science, 318(5854), pp. 1258-65. 
Chien, E. Y., Liu, W., Zhao, Q., Katritch, V., Han, G. W., Hanson, M. A., Shi, L., Newman, A. H., 
Javitch, J. A., Cherezov, V. and Stevens, R. C. (2010) 'Structure of the human 
dopamine D3 receptor in complex with a D2/D3 selective antagonist', Science, 
330(6007), pp. 1091-5. 
Clozel, M., Fischli, W. and Guilly, C. (1989) 'Specific binding of endothelin on human vascular 
smooth muscle cells in culture', J Clin Invest, 83(5), pp. 1758-61. 
Colson, A. O., Perlman, J. H., Smolyar, A., Gershengorn, M. C. and Osman, R. (1998) 'Static 
and dynamic roles of extracellular loops in G-protein-coupled receptors: a 
mechanism for sequential binding of thyrotropin-releasing hormone to its receptor', 
Biophys J, 74(3), pp. 1087-100. 
Conner, M., Hawtin, S. R., Simms, J., Wootten, D., Lawson, Z., Conner, A. C., Parslow, R. A. 
and Wheatley, M. (2007) 'Systematic analysis of the entire second extracellular loop 
of the V(1a) vasopressin receptor: key residues, conserved throughout a G-protein-
coupled receptor family, identified.', J Biol Chem, 282(24), pp. 17405-12. 
Dong, M., Lam, P. C., Orry, A., Sexton, P. M., Christopoulos, A., Abagyan, R. and Miller, L. J. 
(2016) 'Use of Cysteine Trapping to Map Spatial Approximations between Residues 
Contributing to the Helix N-capping Motif of Secretin and Distinct Residues within 
Each of the Extracellular Loops of Its Receptor', J Biol Chem, 291(10), pp. 5172-84. 
Dong, M., Xu, X., Ball, A. M., Makhoul, J. A., Lam, P. C., Pinon, D. I., Orry, A., Sexton, P. M., 
Abagyan, R. and Miller, L. J. (2012) 'Mapping spatial approximations between the 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
amino terminus of secretin and each of the extracellular loops of its receptor using 
cysteine trapping', FASEB J, 26(12), pp. 5092-105. 
Dore, A. S., Okrasa, K., Patel, J. C., Serrano-Vega, M., Bennett, K., Cooke, R. M., Errey, J. C., 
Jazayeri, A., Khan, S., Tehan, B., Weir, M., Wiggin, G. R. and Marshall, F. H. (2014) 
'Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane 
domain', Nature, 511(7511), pp. 557-62. 
Fischli, W., Clozel, M. and Guilly, C. (1989) 'Specific receptors for endothelin on membranes 
from human placenta. Characterization and use in a binding assay', Life Sci, 44(20), 
pp. 1429-36. 
Fitzpatrick, V. D. and Vandlen, R. L. (1994) '6agonist selectivity determinants in somatostatin 
receptor subtypes I and II', J Biol Chem, 269(40), pp. 24621-6. 
Fredriksson, R., Lagerstrom, M. C., Lundin, L. G. and Schioth, H. B. (2003) 'The G-protein-
coupled receptors in the human genome form five main families. Phylogenetic 
analysis, paralogon groups, and fingerprints', Mol Pharmacol, 63(6), pp. 1256-72. 
Gil-Mast, S., Kortagere, S., Kota, K. and Kuzhikandathil, E. V. (2013) 'An amino acid residue in 
the second extracellular loop determines the agonist-dependent tolerance property 
of the human D3 dopamine receptor', ACS Chem Neurosci, 4(6), pp. 940-51. 
Gkountelias, K., Tselios, T., Venihaki, M., Deraos, G., Lazaridis, I., Rassouli, O., Gravanis, A. 
and Liapakis, G. (2009) 'Alanine scanning mutagenesis of the second extracellular 
loop of type 1 corticotropin-releasing factor receptor revealed residues critical for 
peptide binding', Mol Pharmacol, 75(4), pp. 793-800. 
Granier, S., Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Weis, W. I. and Kobilka, B. K. 
(2012) 'Structure of the delta-opioid receptor bound to naltrindole', Nature, 
485(7398), pp. 400-4. 
Gregory, K. J., Hall, N. E., Tobin, A. B., Sexton, P. M. and Christopoulos, A. (2010) 
'Identification of orthosteric and allosteric site mutations in M2 muscarinic 
acetylcholine receptors that contribute to ligand-selective signaling bias', J Biol 
Chem, 285(10), pp. 7459-74. 
Haga, K., Kruse, A. C., Asada, H., Yurugi-Kobayashi, T., Shiroishi, M., Zhang, C., Weis, W. I., 
Okada, T., Kobilka, B. K., Haga, T. and Kobayashi, T. (2012) 'Structure of the human 
M2 muscarinic acetylcholine receptor bound to an antagonist', Nature, 482(7386), 
pp. 547-51. 
Hanson, M. A., Roth, C. B., Jo, E., Griffith, M. T., Scott, F. L., Reinhart, G., Desale, H., Clemons, 
B., Cahalan, S. M., Schuerer, S. C., Sanna, M. G., Han, G. W., Kuhn, P., Rosen, H. and 
Stevens, R. C. (2012) 'Crystal structure of a lipid G protein-coupled receptor', Science, 
335(6070), pp. 851-5. 
Hollenstein, K., Kean, J., Bortolato, A., Cheng, R. K., Dore, A. S., Jazayeri, A., Cooke, R. M., 
Weir, M. and Marshall, F. H. (2013) 'Structure of class B GPCR corticotropin-releasing 
factor receptor 1', Nature, 499(7459), pp. 438-43. 
Holst, B. and Schwartz, T. W. (2003) 'Molecular mechanism of agonism and inverse agonism 
in the melanocortin receptors: Zn(2+) as a structural and functional probe', Ann N Y 
Acad Sci, 994, pp. 1-11. 
Hu, J., Feng, Z., Ma, S., Zhang, Y., Tong, Q., Alqarni, M. H., Gou, X. and Xie, X. Q. (2016) 
'Difference and Influence of Inactive and Active States of Cannabinoid Receptor 
Subtype CB2: From Conformation to Drug Discovery', J Chem Inf Model, 56(6), pp. 
1152-63. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
18 
 
Huang, W., Manglik, A., Venkatakrishnan, A. J., Laeremans, T., Feinberg, E. N., Sanborn, A. L., 
Kato, H. E., Livingston, K. E., Thorsen, T. S., Kling, R. C., Granier, S., Gmeiner, P., 
Husbands, S. M., Traynor, J. R., Weis, W. I., Steyaert, J., Dror, R. O. and Kobilka, B. K. 
(2015) 'Structural insights into micro-opioid receptor activation', Nature, 524(7565), 
pp. 315-21. 
Jaakola, V., Griffith, M., Hanson, M., Cherezov, V., Chien, E., Lane, J., Ijzerman, A. and 
Stevens, R. (2008) 'The 2.6 angstrom crystal structure of a human A2A adenosine 
receptor bound to an antagonist.', Science, 322(5905), pp. 1211-7. 
Jazayeri, A., Dias, J. M. and Marshall, F. H. (2015) 'From G Protein-coupled Receptor 
Structure Resolution to Rational Drug Design', J Biol Chem, 290(32), pp. 19489-95. 
Jazayeri, A., Dore, A. S., Lamb, D., Krishnamurthy, H., Southall, S. M., Baig, A. H., Bortolato, 
A., Koglin, M., Robertson, N. J., Errey, J. C., Andrews, S. P., Teobald, I., Brown, A. J., 
Cooke, R. M., Weir, M. and Marshall, F. H. (2016) 'Extra-helical binding site of a 
glucagon receptor antagonist', Nature, 533(7602), pp. 274-7. 
Kennedy, D. P., McRobb, F. M., Leonhardt, S. A., Purdy, M., Figler, H., Marshall, M. A., 
Chordia, M., Figler, R., Linden, J., Abagyan, R. and Yeager, M. (2014) 'The second 
extracellular loop of the adenosine A1 receptor mediates activity of allosteric 
enhancers', Mol Pharmacol, 85(2), pp. 301-9. 
Keov, P., Lopez, L., Devine, S. M., Valant, C., Lane, J. R., Scammells, P. J., Sexton, P. M. and 
Christopoulos, A. (2014) 'Molecular mechanisms of bitopic ligand engagement with 
the M1 muscarinic acetylcholine receptor', J Biol Chem, 289(34), pp. 23817-37. 
Kim, J., Jiang, Q., Glashofer, M., Yehle, S., Wess, J. and Jacobson, K. A. (1996) 'Glutamate 
residues in the second extracellular loop of the human A2a adenosine receptor are 
required for ligand recognition', Mol Pharmacol, 49(4), pp. 683-91. 
Klco, J. M., Wiegand, C. B., Narzinski, K. and Baranski, T. J. (2005) 'Essential role for the 
second extracellular loop in C5a receptor activation', Nat Struct Mol Biol, 12(4), pp. 
320-6. 
Koole, C., Wootten, D., Simms, J., Miller, L. J., Christopoulos, A. and Sexton, P. M. (2012) 
'Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a 
critical role in GLP-1 peptide binding and receptor activation', J Biol Chem, 287(6), 
pp. 3642-58. 
Kruse, A. C., Hu, J., Pan, A. C., Arlow, D. H., Rosenbaum, D. M., Rosemond, E., Green, H. F., 
Liu, T., Chae, P. S., Dror, R. O., Shaw, D. E., Weis, W. I., Wess, J. and Kobilka, B. K. 
(2012) 'Structure and dynamics of the M3 muscarinic acetylcholine receptor', 
Nature, 482(7386), pp. 552-6. 
Kruse, A. C., Ring, A. M., Manglik, A., Hu, J., Hu, K., Eitel, K., Hübner, H., Pardon, E., Valant, 
C., Sexton, P. M., Christopoulos, A., Felder, C. C., Gmeiner, P., Steyaert, J., Weis, W. I., 
Garcia, K. C., Wess, J. and Kobilka, B. K. (2013) 'Activation and allosteric modulation 
of a muscarinic acetylcholine receptor', Nature, 504(7478), pp. 101-6. 
Lebon, G., Warne, T., Edwards, P. C., Bennett, K., Langmead, C. J., Leslie, A. G. and Tate, C. G. 
(2011) 'Agonist-bound adenosine A2A receptor structures reveal common features 
of GPCR activation', Nature, 474(7352), pp. 521-5. 
Leu, F. P. and Nandi, M. (2010) 'GPCR somatostatin receptor extracellular loop 2 is a key 
ectodomain for making subtype-selective antibodies with agonist-like activities in 
the pancreatic neuroendocrine tumor BON cell line', Pancreas, 39(8), pp. 1155-66. 
Lundstrom, L., Bissantz, C., Beck, J., Wettstein, J. G., Woltering, T. J., Wichmann, J. and Gatti, 
S. (2011) 'Structural determinants of allosteric antagonism at metabotropic 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
glutamate receptor 2: mechanistic studies with new potent negative allosteric 
modulators', Br J Pharmacol, 164(2b), pp. 521-37. 
Luttrell, L. M. (2014) 'Minireview: More than just a hammer: ligand "bias" and 
pharmaceutical discovery', Mol Endocrinol, 28(3), pp. 281-94. 
Magnani, F., Pappas, C. G., Crook, T., Magafa, V., Cordopatis, P., Ishiguro, S., Ohta, N., 
Selent, J., Bosnyak, S., Jones, E. S., Gerothanassis, I. P., Tamura, M., Widdop, R. E. and 
Tzakos, A. G. (2014) 'Electronic sculpting of ligand-GPCR subtype selectivity: the case 
of angiotensin II', ACS Chem Biol, 9(7), pp. 1420-5. 
Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., Sunahara, R. K., Pardo, 
L., Weis, W. I., Kobilka, B. K. and Granier, S. (2012) 'Crystal structure of the micro-
opioid receptor bound to a morphinan antagonist', Nature, 485(7398), pp. 321-6. 
Mann, R. J., Al-Sabah, S., de Maturana, R. L., Sinfield, J. K. and Donnelly, D. (2010) 
'Functional coupling of Cys-226 and Cys-296 in the glucagon-like peptide-1 (GLP-1) 
receptor indicates a disulfide bond that is close to the activation pocket', Peptides, 
31(12), pp. 2289-93. 
Mente, S., Guilmette, E., Salafia, M. and Gray, D. (2015) 'Dopamine D1 receptor-agonist 
interactions: A mutagenesis and homology modeling study', Bioorg Med Chem Lett, 
25(10), pp. 2106-11. 
Moro, S., Hoffmann, C. and Jacobson, K. A. (1999) 'Role of the extracellular loops of G 
protein-coupled receptors in ligand recognition: a molecular modeling study of the 
human P2Y1 receptor', Biochemistry, 38(12), pp. 3498-507. 
Naranjo, A. N., Chevalier, A., Cousins, G. D., Ayettey, E., McCusker, E. C., Wenk, C. and 
Robinson, A. S. (2015) 'Conserved disulfide bond is not essential for the adenosine 
A2A receptor: Extracellular cysteines influence receptor distribution within the cell 
and ligand-binding recognition', Biochim Biophys Acta, 1848(2), pp. 603-14. 
Olah, M. E., Jacobson, K. A. and Stiles, G. L. (1994) 'Role of the second extracellular loop of 
adenosine receptors in agonist and antagonist binding. Analysis of chimeric A1/A3 
adenosine receptors', J Biol Chem, 269(40), pp. 24692-8. 
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Le Trong, I., 
Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M. and Miyano, M. (2000) 
'Crystal structure of rhodopsin: A G protein-coupled receptor', Science, 289(5480), 
pp. 739-45. 
Park, S. H., Das, B. B., Casagrande, F., Tian, Y., Nothnagel, H. J., Chu, M., Kiefer, H., Maier, K., 
De Angelis, A. A., Marassi, F. M. and Opella, S. J. (2012) 'Structure of the chemokine 
receptor CXCR1 in phospholipid bilayers', Nature, 491(7426), pp. 779-83. 
Peeters, M. C., Wisse, L. E., Dinaj, A., Vroling, B., Vriend, G. and Ijzerman, A. P. (2012) 'The 
role of the second and third extracellular loops of the adenosine A1 receptor in 
activation and allosteric modulation', Biochem Pharmacol, 84(1), pp. 76-87. 
Perlman, J. H., Colson, A. O., Jain, R., Czyzewski, B., Cohen, L. A., Osman, R. and 
Gershengorn, M. C. (1997) 'Role of the extracellular loops of the thyrotropin-
releasing hormone receptor: evidence for an initial interaction with thyrotropin-
releasing hormone', Biochemistry, 36(50), pp. 15670-6. 
Rasmussen, S. G., Choi, H. J., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., Devree, B. T., 
Rosenbaum, D. M., Thian, F. S., Kobilka, T. S., Schnapp, A., Konetzki, I., Sunahara, R. 
K., Gellman, S. H., Pautsch, A., Steyaert, J., Weis, W. I. and Kobilka, B. K. (2011a) 
'Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor', Nature, 
469(7329), pp. 175-80. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
Rasmussen, S. G., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., 
Chae, P. S., Pardon, E., Calinski, D., Mathiesen, J. M., Shah, S. T., Lyons, J. A., Caffrey, 
M., Gellman, S. H., Steyaert, J., Skiniotis, G., Weis, W. I., Sunahara, R. K. and Kobilka, 
B. K. (2011b) 'Crystal structure of the beta2 adrenergic receptor-Gs protein complex', 
Nature, 477(7366), pp. 549-55. 
Rosenbaum, D. M., Rasmussen, S. G. and Kobilka, B. K. (2009) 'The structure and function of 
G-protein-coupled receptors', Nature, 459(7245), pp. 356-63. 
Salon, J. A., Lodowski, D. T. and Palczewski, K. (2011) 'The significance of G protein-coupled 
receptor crystallography for drug discovery', Pharmacol Rev, 63(4), pp. 901-37. 
Shihoya, W., Nishizawa, T., Okuta, A., Tani, K., Dohmae, N., Fujiyoshi, Y., Nureki, O. and Doi, 
T. (2016) 'Activation mechanism of endothelin ETB receptor by endothelin-1', 
Nature, 537(7620), pp. 363-368. 
Shimamura, T., Shiroishi, M., Weyand, S., Tsujimoto, H., Winter, G., Katritch, V., Abagyan, R., 
Cherezov, V., Liu, W., Han, G. W., Kobayashi, T., Stevens, R. C. and Iwata, S. (2011) 
'Structure of the human histamine H1 receptor complex with doxepin', Nature, 
475(7354), pp. 65-70. 
Shukla, A. K., Singh, G. and Ghosh, E. (2014) 'Emerging structural insights into biased GPCR 
signaling', Trends Biochem Sci, 39(12), pp. 594-602. 
Siu, F. Y., He, M., de Graaf, C., Han, G. W., Yang, D., Zhang, Z., Zhou, C., Xu, Q., Wacker, D., 
Joseph, J. S., Liu, W., Lau, J., Cherezov, V., Katritch, V., Wang, M. W. and Stevens, R. 
C. (2013) 'Structure of the human glucagon class B G-protein-coupled receptor', 
Nature, 499(7459), pp. 444-9. 
Soto, A. G., Smith, T. H., Chen, B., Bhattacharya, S., Cordova, I. C., Kenakin, T., Vaidehi, N. 
and Trejo, J. (2015) 'N-linked glycosylation of protease-activated receptor-1 at 
extracellular loop 2 regulates G-protein signaling bias', Proc Natl Acad Sci U S A, 
112(27), pp. E3600-8. 
Sounier, R., Mas, C., Steyaert, J., Laeremans, T., Manglik, A., Huang, W., Kobilka, B. K., 
Demene, H. and Granier, S. (2015) 'Propagation of conformational changes during 
mu-opioid receptor activation', Nature, 524(7565), pp. 375-8. 
Srivastava, A., Yano, J., Hirozane, Y., Kefala, G., Gruswitz, F., Snell, G., Lane, W., Ivetac, A., 
Aertgeerts, K., Nguyen, J., Jennings, A. and Okada, K. (2014) 'High-resolution 
structure of the human GPR40 receptor bound to allosteric agonist TAK-875', Nature, 
513(7516), pp. 124-7. 
Takasuka, T., Sakurai, T., Goto, K., Furuichi, Y. and Watanabe, T. (1994) 'Human endothelin 
receptor ETB. Amino acid sequence requirements for super stable complex 
formation with its ligand', J Biol Chem, 269(10), pp. 7509-13. 
Tan, Q., Zhu, Y., Li, J., Chen, Z., Han, G. W., Kufareva, I., Li, T., Ma, L., Fenalti, G., Li, J., Zhang, 
W., Xie, X., Yang, H., Jiang, H., Cherezov, V., Liu, H., Stevens, R. C., Zhao, Q. and Wu, 
B. (2013) 'Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc 
complex', Science, 341(6152), pp. 1387-90. 
Thal, D. M., Sun, B., Feng, D., Nawaratne, V., Leach, K., Felder, C. C., Bures, M. G., Evans, D. 
A., Weis, W. I., Bachhawat, P., Kobilka, T. S., Sexton, P. M., Kobilka, B. K. and 
Christopoulos, A. (2016) 'Crystal structures of the M1 and M4 muscarinic 
acetylcholine receptors', Nature, 531(7594), pp. 335-40. 
Thompson, A. A., Liu, W., Chun, E., Katritch, V., Wu, H., Vardy, E., Huang, X. P., Trapella, C., 
Guerrini, R., Calo, G., Roth, B. L., Cherezov, V. and Stevens, R. C. (2012) 'Structure of 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
 
the nociceptin/orphanin FQ receptor in complex with a peptide mimetic', Nature, 
485(7398), pp. 395-9. 
Unal, H., Jagannathan, R., Bhat, M. B. and Karnik, S. S. (2010) 'Ligand-specific conformation 
of extracellular loop-2 in the angiotensin II type 1 receptor', J Biol Chem, 285(21), pp. 
16341-50. 
Venkatakrishnan, A. J., Deupi, X., Lebon, G., Tate, C. G., Schertler, G. F. and Babu, M. M. 
(2013) 'Molecular signatures of G-protein-coupled receptors', Nature, 494(7436), pp. 
185-94. 
Wacker, D., Wang, C., Katritch, V., Han, G. W., Huang, X. P., Vardy, E., McCorvy, J. D., Jiang, 
Y., Chu, M., Siu, F. Y., Liu, W., Xu, H. E., Cherezov, V., Roth, B. L. and Stevens, R. C. 
(2013) 'Structural features for functional selectivity at serotonin receptors', Science, 
340(6132), pp. 615-9. 
Walker, P., Munoz, M., Martinez, R. and Peitsch, M. C. (1994) 'Acidic residues in extracellular 
loops of the human Y1 neuropeptide Y receptor are essential for ligand binding', J 
Biol Chem, 269(4), pp. 2863-9. 
Wang, C., Jiang, Y., Ma, J., Wu, H., Wacker, D., Katritch, V., Han, G. W., Liu, W., Huang, X. P., 
Vardy, E., McCorvy, J. D., Gao, X., Zhou, X. E., Melcher, K., Zhang, C., Bai, F., Yang, H., 
Yang, L., Jiang, H., Roth, B. L., Cherezov, V., Stevens, R. C. and Xu, H. E. (2013) 
'Structural basis for molecular recognition at serotonin receptors', Science, 
340(6132), pp. 610-4. 
Warne, T., Serrano-Vega, M. J., Baker, J. G., Moukhametzianov, R., Edwards, P. C., 
Henderson, R., Leslie, A. G., Tate, C. G. and Schertler, G. F. (2008) 'Structure of a 
beta1-adrenergic G-protein-coupled receptor', Nature, 454(7203), pp. 486-91. 
Weston, C., Winfield, I., Harris, M., Hodgson, R., Shah, A., Dowell, S. J., Mobarec, J. C., 
Woodcock, D. A., Reynolds, C. A., Poyner, D. R., Watkins, H. A. and Ladds, G. (2016) 
'Receptor activity modifying protein-directed G protein signaling specificity for the 
calcitonin gene-related peptide family of receptors', J Biol Chem. 
Wheatley, M., Wootten, D., Conner, M. T., Simms, J., Kendrick, R., Logan, R. T., Poyner, D. R. 
and Barwell, J. (2012) 'Lifting the lid on GPCRs: the role of extracellular loops', Br J 
Pharmacol, 165(6), pp. 1688-703. 
Wifling, D., Bernhardt, G., Dove, S. and Buschauer, A. (2015a) 'The extracellular loop 2 
(ECL2) of the human histamine H4 receptor substantially contributes to ligand 
binding and constitutive activity', PLoS One, 10(1), pp. e0117185. 
Wifling, D., Loffel, K., Nordemann, U., Strasser, A., Bernhardt, G., Dove, S., Seifert, R. and 
Buschauer, A. (2015b) 'Molecular determinants for the high constitutive activity of 
the human histamine H4 receptor: functional studies on orthologues and mutants', 
Br J Pharmacol, 172(3), pp. 785-98. 
Woolley, M. J., Watkins, H. A., Taddese, B., Karakullukcu, Z. G., Barwell, J., Smith, K. J., Hay, 
D. L., Poyner, D. R., Reynolds, C. A. and Conner, A. C. (2013) 'The role of ECL2 in CGRP 
receptor activation: a combined modelling and experimental approach', J R Soc 
Interface, 10(88), pp. 20130589. 
Wootten, D., Reynolds, C. A., Smith, K. J., Mobarec, J. C., Koole, C., Savage, E. E., Pabreja, K., 
Simms, J., Sridhar, R., Furness, S. G., Liu, M., Thompson, P. E., Miller, L. J., 
Christopoulos, A. and Sexton, P. M. (2016) 'The Extracellular Surface of the GLP-1 
Receptor Is a Molecular Trigger for Biased Agonism', Cell, 165(7), pp. 1632-43. 
Wu, B., Chien, E. Y., Mol, C. D., Fenalti, G., Liu, W., Katritch, V., Abagyan, R., Brooun, A., 
Wells, P., Bi, F. C., Hamel, D. J., Kuhn, P., Handel, T. M., Cherezov, V. and Stevens, R. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
22 
 
C. (2010) 'Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic 
peptide antagonists', Science, 330(6007), pp. 1066-71. 
Wu, H., Wacker, D., Mileni, M., Katritch, V., Han, G. W., Vardy, E., Liu, W., Thompson, A. A., 
Huang, X. P., Carroll, F. I., Mascarella, S. W., Westkaemper, R. B., Mosier, P. D., Roth, 
B. L., Cherezov, V. and Stevens, R. C. (2012) 'Structure of the human kappa-opioid 
receptor in complex with JDTic', Nature, 485(7398), pp. 327-32. 
Wu, H., Wang, C., Gregory, K. J., Han, G. W., Cho, H. P., Xia, Y., Niswender, C. M., Katritch, V., 
Meiler, J., Cherezov, V., Conn, P. J. and Stevens, R. C. (2014) 'Structure of a class C 
GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator', Science, 
344(6179), pp. 58-64. 
Zhang, C., Srinivasan, Y., Arlow, D. H., Fung, J. J., Palmer, D., Zheng, Y., Green, H. F., Pandey, 
A., Dror, R. O., Shaw, D. E., Weis, W. I., Coughlin, S. R. and Kobilka, B. K. (2012) 'High-
resolution crystal structure of human protease-activated receptor 1', Nature, 
492(7429), pp. 387-92. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Highlights 
 
Understanding the common themes and diverse roles of the second 
extracellular loop (ECL2) of the GPCR super-family.  
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• Extracellular loop 2 (ECL2) is a key GPCR domain. 
• ECL2 is usually a β-hairpin but can form other structures.  
• ECL2 can be directly involved with the ligand-receptor functions. 
• ECL2 is also involved in as biased agonism and allosteric modulation. 
• These properties of ECL2 make it an important site for rational drug design. 
 
